TR 393 Mouse Pathology Tables
INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)
SODIUM FLUORIDE
NTP Experiment-Test: 05131-02 Report: PEIRPT05
Study Type: CHRONIC Date: 09/17/94
Route: DOSED WATER Time: 08:28:02
Facility: Battelle Columbus Laboratory
Chemical CAS #: 7681-49-4
Lock Date: None
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05131-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC SODIUM FLUORIDE Date: 09/17/94
Route: DOSED WATER Time: 08:28:02
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 PPM SPECIAL 25 PPM 100 PPM 175 PPM
CONTROL
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 100 50 70 70 99
Scheduled Sacrifice 20 18 20 19
Early Deaths
Natural Death 13 7 5 7 16
Moribund Sacrifice 14 6 9 9 12
Survivors
Terminal Sacrifice 53 8 38 32 51
Natural Death 2 1
Special Control 29
Animals Examined Microscopically 100 42 62 63 99
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (99) (40) (59) (58) (98)
Histiocytic Sarcoma 1 (2%) 1 (1%)
Intestine Large, Cecum (100) (42) (60) (59) (97)
Intestine Large, Rectum (99) (42) (60) (59) (98)
Histiocytic Sarcoma 1 (2%)
Intestine Small, Duodenum (100) (42) (60) (58) (98)
Fibrosarcoma, Metastatic, Skin 1 (1%)
Histiocytic Sarcoma 1 (2%)
Intestine Small, Ileum (98) (42) (60) (59) (97)
Fibrosarcoma, Metastatic, Skin 1 (2%)
Histiocytic Sarcoma 1 (2%)
Intestine Small, Jejunum (100) (42) (60) (59) (97)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 1 (2%)
Liver (100) (42) (60) (60) (99)
Hemangioma 1 (1%) 1 (2%) 1 (1%)
Hemangiosarcoma 2 (2%) 1 (2%) 1 (1%)
Hepatoblastoma 1 (2%) 2 (2%)
Hepatocellular Carcinoma 13 (13%) 3 (7%) 9 (15%) 7 (12%) 12 (12%)
Hepatocellular Carcinoma, Multiple 1 (1%) 2 (3%) 1 (2%) 1 (1%)
Hepatocellular Adenoma 25 (25%) 4 (10%) 11 (18%) 12 (20%) 19 (19%)
Hepatocellular Adenoma, Multiple 27 (27%) 5 (12%) 21 (35%) 14 (23%) 17 (17%)
Hepatocholangiocarcinoma 1 (2%) 1 (1%)
Histiocytic Sarcoma 4 (4%) 1 (2%) 2 (3%) 5 (5%)
Osteosarcoma, Metastatic, Bone 1 (1%)
Osteosarcoma, Metastatic, Uncertain Primary
Site 1 (2%)
Mesentery (28) (6) (16) (18) (28)
Fibrosarcoma, Metastatic, Skin 1 (4%) 1 (17%) 1 (6%)
Page 2
NTP Experiment-Test: 05131-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC SODIUM FLUORIDE Date: 09/17/94
Route: DOSED WATER Time: 08:28:02
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 PPM SPECIAL 25 PPM 100 PPM 175 PPM
CONTROL
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
Hemangioma 1 (6%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (4%)
Histiocytic Sarcoma 2 (7%) 2 (13%) 1 (6%) 3 (11%)
Lipoma 1 (4%)
Sarcoma, Metastatic, Uncertain Primary Site 1 (4%)
Pancreas (100) (42) (60) (59) (98)
Fibrosarcoma, Metastatic, Skin 1 (1%) 1 (2%)
Hepatoblastoma, Metastatic, Liver 1 (1%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (1%)
Histiocytic Sarcoma 2 (2%) 2 (3%) 1 (2%) 1 (1%)
Acinus, Adenocarcinoma 1 (1%)
Salivary Glands (99) (41) (60) (60) (99)
Histiocytic Sarcoma 1 (1%)
Stomach, Forestomach (100) (42) (60) (59) (98)
Mast Cell Tumor Malignant 1 (2%)
Squamous Cell Papilloma 3 (3%) 4 (7%) 2 (3%) 3 (3%)
Squamous Cell Papilloma, Multiple 1 (1%)
Stomach, Glandular (100) (42) (60) (59) (98)
Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (99) (41) (60) (60) (99)
Hemangiosarcoma 1 (2%)
Hemangiosarcoma, Metastatic, Liver 1 (1%)
Hepatoblastoma, Metastatic, Liver 1 (1%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 2 (2%) 1 (2%) 2 (2%)
Pericardium, Hepatocholangiocarcinoma,
Metastatic, Liver 1 (1%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland, Cortex (99) (42) (60) (60) (99)
Histiocytic Sarcoma 1 (2%) 2 (3%) 1 (1%)
Sarcoma, Metastatic, Uncertain Primary Site 1 (1%)
Adrenal Gland, Medulla (96) (42) (60) (60) (98)
Pheochromocytoma Benign 1 (2%) 1 (2%) 1 (1%)
Bilateral, Pheochromocytoma Benign 1 (2%)
Islets, Pancreatic (99) (41) (60) (59) (99)
Adenoma 1 (1%) 1 (2%) 1 (2%) 1 (1%)
Fibrosarcoma, Metastatic, Skin 1 (2%)
Histiocytic Sarcoma 1 (2%)
Pituitary Gland (100) (41) (59) (61) (97)
Histiocytic Sarcoma 2 (2%)
Page 3
NTP Experiment-Test: 05131-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC SODIUM FLUORIDE Date: 09/17/94
Route: DOSED WATER Time: 08:28:02
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 PPM SPECIAL 25 PPM 100 PPM 175 PPM
CONTROL
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM - cont
Pars Distalis, Adenoma 22 (22%) 3 (7%) 6 (10%) 8 (13%) 13 (13%)
Pars Distalis, Adenoma, Multiple 3 (3%) 1 (2%)
Thyroid Gland (100) (42) (60) (60) (99)
C-Cell, Carcinoma 1 (2%)
Follicular Cell, Adenocarcinoma 1 (2%)
Follicular Cell, Adenoma 3 (3%) 2 (5%) 2 (2%)
Follicular Cell, Adenoma, Multiple 1 (1%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ovary (98) (41) (57) (58) (98)
Cystadenoma 1 (1%)
Cystadenoma, Papillary 3 (3%) 1 (2%) 1 (1%)
Fibrosarcoma, Metastatic, Skin 1 (1%) 1 (2%)
Granulosa Cell Tumor Benign 1 (1%)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 2 (2%) 1 (2%) 1 (2%) 3 (3%)
Luteoma 1 (1%)
Sarcoma, Metastatic, Uncertain Primary Site 1 (1%)
Uterus (100) (42) (60) (60) (99)
Hemangioma 2 (2%)
Hemangiosarcoma 1 (2%) 1 (2%)
Histiocytic Sarcoma 4 (4%) 1 (2%) 1 (2%) 4 (4%)
Polyp Stromal 3 (3%) 1 (2%) 1 (2%) 1 (1%)
Sarcoma Stromal 1 (1%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Blood (2) (1)
Histiocytic Sarcoma 1 (50%)
Bone Marrow (100) (42) (62) (61) (99)
Femoral, Hemangiosarcoma 1 (1%) 1 (2%) 1 (2%)
Femoral, Histiocytic Sarcoma 2 (2%) 1 (2%) 2 (2%)
Humerus, Hemangiosarcoma 1 (2%)
Humerus, Histiocytic Sarcoma 1 (1%)
Maxilla, Histiocytic Sarcoma 1 (1%)
Thoracic, Vertebra, Histiocytic Sarcoma 1 (1%)
Tibia, Histiocytic Sarcoma 2 (2%)
Lymph Node (100) (42) (60) (60) (99)
Inguinal, Histiocytic Sarcoma 1 (1%)
Page 4
NTP Experiment-Test: 05131-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC SODIUM FLUORIDE Date: 09/17/94
Route: DOSED WATER Time: 08:28:02
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 PPM SPECIAL 25 PPM 100 PPM 175 PPM
CONTROL
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - cont
Lumbar, Fibrosarcoma, Metastatic, Skin 1 (2%)
Lumbar, Histiocytic Sarcoma 1 (1%)
Mediastinal, Hepatoblastoma, Metastatic,
Liver 1 (1%)
Mediastinal, Hepatocholangiocarcinoma,
Metastatic, Liver 1 (2%)
Mediastinal, Histiocytic Sarcoma 1 (1%) 2 (3%) 1 (2%) 2 (2%)
Renal, Fibrosarcoma, Metastatic, Skin 1 (2%)
Renal, Histiocytic Sarcoma 1 (1%)
Lymph Node, Mandibular (96) (42) (60) (56) (98)
Hemangioma 1 (1%)
Histiocytic Sarcoma 3 (3%) 1 (2%) 3 (3%)
Lymph Node, Mesenteric (99) (40) (57) (57) (94)
Fibrosarcoma, Metastatic, Skin 1 (3%)
Hemangioma 1 (1%)
Histiocytic Sarcoma 2 (2%) 1 (2%) 1 (2%) 3 (3%)
Spleen (99) (42) (60) (59) (99)
Hemangiosarcoma 1 (1%)
Histiocytic Sarcoma 1 (1%) 2 (3%) 1 (2%) 2 (2%)
Thymus (96) (42) (56) (55) (92)
Histiocytic Sarcoma 1 (1%) 1 (2%) 2 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (98) (41) (59) (60) (99)
Adenocarcinoma 1 (1%) 1 (2%)
Adenoma 1 (1%)
Histiocytic Sarcoma 1 (2%)
Skin (100) (42) (60) (60) (99)
Histiocytic Sarcoma 1 (2%)
Subcutaneous Tissue, Fibrosarcoma 2 (2%) 2 (5%) 2 (3%) 5 (5%)
Subcutaneous Tissue, Hemangiosarcoma 1 (2%)
Subcutaneous Tissue, Mast Cell Tumor
Malignant 1 (2%)
Subcutaneous Tissue, Neurofibrosarcoma 1 (1%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (90) (42) (60) (60) (89)
Femur, Osteosarcoma 1 (1%)
Femur, Synovial Tissue, Sarcoma 1 (1%)
Humerus, Hemangiosarcoma 1 (1%)
Maxilla, Adenocarcinoma, Metastatic,
Harderian Gland 1 (1%)
Rib, Osteoma 1 (1%)
Page 5
NTP Experiment-Test: 05131-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC SODIUM FLUORIDE Date: 09/17/94
Route: DOSED WATER Time: 08:28:02
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 PPM SPECIAL 25 PPM 100 PPM 175 PPM
CONTROL
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM - cont
Skeletal Muscle (12) (1) (1) (11)
Fibrosarcoma, Metastatic, Skin 1 (9%)
Histiocytic Sarcoma 1 (8%) 1 (100%)
Osteosarcoma, Metastatic, Bone 1 (8%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (100) (42) (60) (60) (99)
Histiocytic Sarcoma 1 (1%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (100) (42) (60) (60) (99)
Adenocarcinoma, Metastatic, Harderian Gland 1 (1%) 1 (2%)
Alveolar/Bronchiolar Adenoma 5 (5%) 2 (5%) 3 (5%) 2 (3%) 4 (4%)
Alveolar/Bronchiolar Adenoma, Multiple 1 (2%)
Alveolar/Bronchiolar Carcinoma 3 (3%) 2 (3%) 2 (3%) 3 (3%)
Fibrosarcoma, Metastatic, Skin 1 (1%)
Hepatoblastoma, Metastatic, Liver 1 (1%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (1%) 1 (2%) 1 (2%) 2 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%) 1 (1%)
Histiocytic Sarcoma 3 (3%) 1 (2%) 2 (3%) 3 (3%)
Osteosarcoma, Metastatic, Bone 1 (1%)
Osteosarcoma, Metastatic, Uncertain Primary
Site 1 (2%)
Mediastinum, Fibrosarcoma, Metastatic, Skin 1 (1%)
Mediastinum, Hepatocellular Carcinoma,
Metastatic, Liver 1 (1%)
Nose (100) (42) (60) (60) (99)
Adenocarcinoma, Metastatic, Harderian Gland 1 (1%)
Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Ear (1) (1) (1)
Fibrosarcoma 1 (100%)
Squamous Cell Papilloma 1 (100%)
Harderian Gland (66) (36) (48) (45) (52)
Adenocarcinoma 1 (2%) 1 (2%)
Adenoma 4 (6%) 1 (3%) 2 (4%) 7 (16%) 2 (4%)
____________________________________________________________________________________________________________________________________
Page 6
NTP Experiment-Test: 05131-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC SODIUM FLUORIDE Date: 09/17/94
Route: DOSED WATER Time: 08:28:02
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 PPM SPECIAL 25 PPM 100 PPM 175 PPM
CONTROL
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (100) (42) (60) (60) (99)
Fibrosarcoma, Metastatic, Skin 1 (1%)
Histiocytic Sarcoma 3 (3%) 2 (3%) 1 (2%) 4 (4%)
Urinary Bladder (100) (42) (60) (60) (97)
Histiocytic Sarcoma 3 (3%) 1 (2%) 1 (1%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(100) *(42) *(62) *(63) *(99)
Histiocytic Sarcoma 5 (5%) 3 (5%) 2 (3%) 5 (5%)
Lymphoma Malignant Lymphocytic 2 (2%) 1 (2%) 5 (5%)
Lymphoma Malignant Mixed 4 (4%) 5 (8%) 7 (11%) 8 (8%)
Lymphoma Malignant Undifferentiated Cell 5 (5%) 1 (2%) 3 (5%) 6 (6%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 7
NTP Experiment-Test: 05131-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC SODIUM FLUORIDE Date: 09/17/94
Route: DOSED WATER Time: 08:28:02
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 PPM SPECIAL 25 PPM 100 PPM 175 PPM
CONTROL
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 77 17 45 40 65
Total Primary Neoplasms 152 27 88 78 121
Total Animals with Benign Neoplasms 69 12 38 32 48
Total Benign Neoplasms 107 17 56 49 70
Total Animals with Malignant Neoplasms 35 9 26 25 44
Total Malignant Neoplasms 45 10 32 29 51
Total Animals with Metastatic Neoplasms 5 2 4 1 8
Total Metastatic Neoplasm 13 11 5 1 17
Total Animals with Malignant Neoplasms 1 1
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 8
NTP Experiment-Test: 05131-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC SODIUM FLUORIDE Date: 09/17/94
Route: DOSED WATER Time: 08:28:02
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 PPM SPECIAL 25 PPM 100 PPM 175 PPM
CONTROL
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 99 50 70 70 100
Scheduled Sacrifice 20 20 19 20
Early Deaths
Natural Death 16 3 8 6 11
Moribund Sacrifice 5 9 3 8 4
Survivors
Natural Death 2
Terminal Sacrifice 56 18 39 37 65
Special Control 20
Animals Examined Microscopically 99 32 60 62 100
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Large, Cecum (99) (32) (60) (59) (100)
Adenocarcinoma, Metastatic, Intestine Large 1 (1%)
Intestine Large, Colon (99) (32) (60) (59) (100)
Adenocarcinoma 1 (1%)
Intestine Small, Duodenum (99) (32) (60) (59) (100)
Polyp Adenomatous 2 (3%) 1 (1%)
Intestine Small, Ileum (98) (32) (60) (58) (100)
Adenocarcinoma, Metastatic, Intestine Large 1 (1%)
Intestine Small, Jejunum (99) (32) (60) (59) (100)
Adenocarcinoma 1 (2%) 1 (2%)
Liver (99) (32) (60) (61) (100)
Adenocarcinoma, Metastatic, Stomach 1 (2%)
Fibrosarcoma, Metastatic, Prostate 1 (2%)
Hemangiosarcoma 3 (3%) 1 (3%) 2 (3%) 2 (2%)
Hemangiosarcoma, Multiple 1 (1%) 1 (2%) 1 (1%)
Hemangiosarcoma, Multiple, Metastatic, Liver 1 (3%)
Hemangiosarcoma, Metastatic, Heart 1 (2%)
Hemangiosarcoma, Metastatic, Spleen 1 (1%)
Hepatoblastoma 1 (2%) 1 (2%) 3 (3%)
Hepatocellular Carcinoma 19 (19%) 7 (22%) 11 (18%) 14 (23%) 13 (13%)
Hepatocellular Carcinoma, Multiple 6 (6%) 4 (7%) 2 (2%)
Hepatocellular Adenoma 16 (16%) 8 (25%) 20 (33%) 5 (8%) 28 (28%)
Hepatocellular Adenoma, Multiple 38 (38%) 7 (22%) 19 (32%) 27 (44%) 30 (30%)
Histiocytic Sarcoma 1 (3%) 1 (2%) 1 (1%)
Mesentery (10) (2) (5) (8) (4)
Adenocarcinoma, Metastatic, Intestine Large 1 (25%)
Fibrosarcoma, Metastatic, Prostate 1 (20%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (13%)
Histiocytic Sarcoma 1 (50%)
Page 9
NTP Experiment-Test: 05131-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC SODIUM FLUORIDE Date: 09/17/94
Route: DOSED WATER Time: 08:28:02
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 PPM SPECIAL 25 PPM 100 PPM 175 PPM
CONTROL
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
Pancreas (98) (32) (60) (60) (100)
Fibrosarcoma, Metastatic, Prostate 1 (2%)
Hemangioma 1 (2%)
Salivary Glands (98) (32) (60) (60) (100)
Histiocytic Sarcoma 1 (2%)
Stomach, Forestomach (99) (32) (60) (60) (99)
Squamous Cell Papilloma 2 (6%) 1 (1%)
Stomach, Glandular (99) (32) (60) (60) (100)
Adenocarcinoma 1 (2%)
Adenoma 1 (2%)
Fibrosarcoma, Metastatic, Prostate 1 (2%)
Tooth (90) (32) (60) (60) (90)
Incisor, Odontoma 1 (2%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Blood Vessel (3) (1) (1) (2)
Aorta, Alveolar/Bronchiolar Carcinoma,
Metastatic, Lung 1 (50%)
Heart (99) (32) (60) (59) (100)
Hemangiosarcoma 1 (2%)
Hemangiosarcoma, Metastatic, Liver 1 (1%)
Hemangiosarcoma, Metastatic, Skin 1 (1%)
Hemangiosarcoma, Metastatic, Spleen 1 (1%)
Hepatoblastoma, Metastatic, Liver 1 (1%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland, Cortex (99) (32) (60) (60) (100)
Adenoma 1 (1%)
Bilateral, Capsule, Spindle Cell, Adenoma 2 (2%) 1 (3%) 1 (2%) 1 (2%)
Capsule, Spindle Cell, Adenoma 6 (6%) 6 (10%) 5 (8%) 6 (6%)
Capsule, Spindle Cell, Adenoma, Multiple 1 (2%)
Adrenal Gland, Medulla (96) (32) (60) (60) (99)
Pheochromocytoma Malignant 1 (2%)
Pheochromocytoma Benign 1 (2%) 1 (1%)
Islets, Pancreatic (98) (32) (60) (60) (100)
Adenoma 2 (2%)
Thyroid Gland (99) (32) (60) (60) (100)
C-Cell, Adenoma 1 (1%)
Follicular Cell, Adenoma 1 (1%) 1 (3%) 1 (2%) 3 (5%) 2 (2%)
____________________________________________________________________________________________________________________________________
Page 10
NTP Experiment-Test: 05131-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC SODIUM FLUORIDE Date: 09/17/94
Route: DOSED WATER Time: 08:28:02
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 PPM SPECIAL 25 PPM 100 PPM 175 PPM
CONTROL
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (99) (32) (60) (60) (99)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (1%)
Prostate (99) (32) (60) (60) (99)
Fibrosarcoma 1 (2%)
Seminal Vesicle (99) (32) (60) (60) (100)
Fibrosarcoma, Metastatic, Prostate 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Testes (98) (31) (60) (60) (99)
Interstitial Cell, Adenoma 1 (2%) 1 (1%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Blood (2)
Bone Marrow (99) (32) (60) (60) (100)
Femoral, Hemangiosarcoma 1 (2%) 1 (2%)
Femoral, Hemangiosarcoma, Metastatic, Liver 1 (1%)
Femoral, Hemangiosarcoma, Metastatic, Skin 1 (1%) 1 (3%)
Femoral, Hemangiosarcoma, Metastatic, Spleen 1 (1%)
Femoral, Histiocytic Sarcoma 1 (1%)
Humerus, Hemangiosarcoma 2 (3%)
Humerus, Hemangiosarcoma, Metastatic, Skin 1 (1%)
Tibia, Hemangiosarcoma, Metastatic, Skin 1 (1%)
Lymph Node (99) (32) (60) (60) (100)
Bronchial, Alveolar/Bronchiolar Carcinoma,
Metastatic, Lung 1 (1%)
Mediastinal, Alveolar/Bronchiolar Carcinoma,
Metastatic, Lung 1 (2%)
Mediastinal, Fibrosarcoma, Metastatic,
Prostate 1 (2%)
Mediastinal, Hepatoblastoma, Metastatic,
Liver 1 (1%)
Mediastinal, Hepatocellular Carcinoma,
Metastatic, Liver 1 (2%)
Pancreatic, Hepatoblastoma, Metastatic, Liver 1 (1%)
Renal, Hepatoblastoma, Metastatic, Liver 1 (1%)
Lymph Node, Mandibular (98) (31) (60) (59) (100)
Lymph Node, Mesenteric (94) (31) (59) (56) (92)
Adenocarcinoma, Metastatic, Intestine Large 1 (1%)
Page 11
NTP Experiment-Test: 05131-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC SODIUM FLUORIDE Date: 09/17/94
Route: DOSED WATER Time: 08:28:02
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 PPM SPECIAL 25 PPM 100 PPM 175 PPM
CONTROL
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - cont
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%)
Spleen (99) (32) (60) (60) (100)
Hemangiosarcoma 1 (2%) 1 (1%)
Hemangiosarcoma, Metastatic, Liver 1 (1%)
Hemangiosarcoma, Metastatic, Skin 1 (1%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (1%) 1 (3%) 1 (2%)
Thymus (87) (28) (52) (45) (85)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Hepatoblastoma, Metastatic, Liver 1 (1%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (99) (31) (60) (60) (100)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Squamous Cell Papilloma 1 (1%)
Subcutaneous Tissue, Fibrosarcoma 1 (3%)
Subcutaneous Tissue, Hemangiosarcoma 1 (1%) 1 (3%) 1 (2%) 2 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (89) (32) (60) (60) (90)
Cranium, Schwannoma Malignant, Metastatic,
Brain 1 (1%)
Femur, Osteosarcoma 1 (2%)
Humerus, Hemangiosarcoma 1 (2%)
Maxilla, Adenocarcinoma, Metastatic,
Harderian Gland 1 (2%)
Skeletal Muscle (11) (11)
Hepatoblastoma, Metastatic, Liver 1 (9%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (99) (32) (60) (60) (99)
Olfactory Lobe, Schwannoma Malignant 1 (1%)
____________________________________________________________________________________________________________________________________
Page 12
NTP Experiment-Test: 05131-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC SODIUM FLUORIDE Date: 09/17/94
Route: DOSED WATER Time: 08:28:02
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 PPM SPECIAL 25 PPM 100 PPM 175 PPM
CONTROL
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (99) (32) (60) (60) (100)
Adenocarcinoma, Metastatic, Harderian Gland 1 (2%)
Alveolar/Bronchiolar Adenoma 10 (10%) 1 (3%) 4 (7%) 13 (22%) 9 (9%)
Alveolar/Bronchiolar Adenoma, Multiple 2 (2%) 2 (2%)
Alveolar/Bronchiolar Carcinoma 12 (12%) 4 (13%) 8 (13%) 1 (2%) 7 (7%)
Alveolar/Bronchiolar Carcinoma, Multiple 1 (2%)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 2 (2%) 1 (3%) 1 (2%) 2 (2%)
Fibrosarcoma, Metastatic, Skin 1 (3%)
Hemangiosarcoma, Metastatic, Liver 1 (1%)
Hepatoblastoma, Metastatic, Liver 1 (1%)
Hepatocellular Carcinoma, Metastatic, Liver 8 (8%) 2 (6%) 2 (3%) 1 (2%) 1 (1%)
Histiocytic Sarcoma 1 (3%)
Lipoma 1 (2%)
Mediastinum, Alveolar/Bronchiolar Carcinoma,
Metastatic, Lung 1 (1%)
Mediastinum, Fibrosarcoma, Metastatic,
Prostate 1 (2%)
Nose (99) (32) (60) (60) (100)
Adenocarcinoma, Metastatic, Harderian Gland 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Ear (1) (1) (2) (1)
Fibrosarcoma 1 (50%) 1 (100%)
Harderian Gland (85) (27) (49) (52) (75)
Adenocarcinoma 1 (1%) 1 (2%) 1 (1%)
Adenoma 7 (8%) 2 (4%) 2 (3%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (99) (32) (60) (60) (100)
Hepatoblastoma, Metastatic, Liver 1 (1%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (3%) 1 (2%)
Ureter (1)
Transitional Epithelium, Carcinoma 1 (100%)
Urinary Bladder (98) (32) (60) (59) (100)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(99) *(32) *(60) *(62) *(100)
Histiocytic Sarcoma 1 (1%) 1 (3%) 2 (3%) 2 (2%)
* Number of animals with any tissue examined microscopically
Page 13
NTP Experiment-Test: 05131-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC SODIUM FLUORIDE Date: 09/17/94
Route: DOSED WATER Time: 08:28:02
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 PPM SPECIAL 25 PPM 100 PPM 175 PPM
CONTROL
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS - cont
Multiple Organs *(99) *(32) *(60) *(62) *(100)
Lymphoma Malignant Lymphocytic 2 (2%) 1 (3%)
Lymphoma Malignant Mixed 1 (1%) 1 (2%) 3 (5%)
Lymphoma Malignant Undifferentiated Cell 1 (1%) 3 (5%) 1 (1%)
____________________________________________________________________________________________________________________________________
Page 14
NTP Experiment-Test: 05131-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC SODIUM FLUORIDE Date: 09/17/94
Route: DOSED WATER Time: 08:28:02
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 PPM SPECIAL 25 PPM 100 PPM 175 PPM
CONTROL
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 77 24 51 47 74
Total Primary Neoplasms 132 36 99 87 124
Total Animals with Benign Neoplasms 62 17 45 38 62
Total Benign Neoplasms 84 20 60 56 86
Total Animals with Malignant Neoplasms 43 14 32 26 33
Total Malignant Neoplasms 48 16 39 31 38
Total Animals with Metastatic Neoplasms 12 6 6 3 8
Total Metastatic Neoplasm 16 6 15 11 25
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 15
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------
--multipart-boundary
Content-type: text/plain
Range: bytes 91595-91595/91595
--multipart-boundary--